Shares of CRISPR genome-editing firm Caribou fell 62% after announcing workforce reductions and pausing trials for two allogeneic CAR-T therapies. The company's staff numbered 97 people as of February 27.
Shares of CRISPR genome-editing firm Caribou fell 62% after announcing workforce reductions and pausing trials for two allogeneic CAR-T therapies. The company's staff numbered 97 people as of February 27.
@stattimes.bsky.socialAirport handling and visibility emerge as CAR-T logistics gaps
Pharma leaders call for better airport handling, real-time tracking and accountability to protect time-sensitive CAR-T shipments.
#carttherapy #pharmalogistics #cellandgenetherapy #coldchain #immunoact #gpls2026
@itln.bsky.socialIndia’s CAR-T therapy reports no logistics-related failures across 1,000 patients, but shipment visibility, airport handling and accountability remain key challenges for global expansion.
#carttherapy #pharmalogistics #cellandgenetherapy #coldchain #immunoact #immuneeltherapeutics
@pharmaphorum.bsky.social#BristolMyersSquibb's GPRC5D-directed #CARTtherapy, arlocabtagene autoleucel (#arlocel), has shown activity in a phase 2 trial that could underpin future filings for #bloodcancer #multiplemyeloma.
@iwpost.bsky.socialCheaper CAR-T therapy drawing global cancer patients to China#Block2 #CARTTherapy #CellTherapy #China #ChinaCancerTreatment #ChinaMedical